Item 6. SELECTED FINANCIAL DATA. Five Year Financial Summary The following table sets forth our selected historical consolidated financial information for each of the five periods indicated. This information should be read together with “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” and with the consolidated financial statements and related notes included elsewhere in this 2019 Form 10-K including disclosures related to the November 20, 2019 acquisition of Celgene. The selected historical financial information as of and for the years ended December 31, 2019, 2018, 2017, 2016 and 2015 are derived from our audited consolidated financial statements and related notes. (a) Includes current and non-current portion. (b) Prior period amounts were conformed to current period presentation. Amounts in Millions, except per share data 2019 2018 2017 2016 2015 Income Statement Data: Total Revenues $ 26,145 $ 22,561 $ 20,776 $ 19,427 $ 16,560 Net Earnings 3,460 4,947 975 4,507 1,631 Net Earnings/(Loss) Attributable to: Noncontrolling Interest 21 27 (32) 50 66 BMS 3,439 4,920 1,007 4,457 1,565 Net Earnings per Common Share Attributable to BMS: Basic $ 2.02 $ 3.01 $ 0.61 $ 2.67 $ 0.94 Diluted 2.01 3.01 0.61 2.65 0.93 Weighted average common shares outstanding: Basic 1,705 1,633 1,645 1,671 1,667 Diluted 1,712 1,637 1,652 1,680 1,679 Cash dividends paid on BMS common and preferred stock $ 2,679 $ 2,613 $ 2,577 $ 2,547 $ 2,477 Cash dividends declared per common share $ 1.68 $ 1.61 $ 1.57 $ 1.53 $ 1.49 Financial Position Data at December 31: Cash and cash equivalents $ 12,346 $ 6,911 $ 5,421 $ 4,237 $ 2,385 Marketable debt securities (a)(b) 3,814 3,623 3,739 4,724 6,442 Total Assets 129,944 34,986 33,551 33,707 31,748 Long-term debt (a) 46,150 6,895 6,975 6,465 6,550 Equity 51,698 14,127 11,847 16,347 14,424 31